Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study.
Body surface area
Docetaxel
Dosage
Pharmacokinetics
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
08 06 2020
08 06 2020
Historique:
received:
23
12
2019
accepted:
29
05
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Docetaxel (DTX) is a widely used anti-tumour drug, and its dosage is solely determined by body surface area (BSA). Adverse events, such as neutropenia or unsatisfied efficacy, likely occur because of differences in the pharmacokinetics (PK) and pharmacodynamics of patients. Thus, a feasible dosage adjustment method is needed. A total of 209 eligible patients who provided consent were enrolled and randomised into two groups to receive the BSA- and PK-guided dosage adjustments of DTX-based chemotherapy (3 weeks per cycle). The AUC of DTX was detected, and the therapeutic window for Chinese patients was determined. The proportion of patients within the therapeutic window was evaluated. Neutropenia was examined in accordance with the toxicity grading standard suggested by the World Health Organisation. Tumour response was assessed in accordance with Response Evaluation Criteria in Solid Tumors version 1.1. The primary endpoint was the incidence of neutropenia, and the secondary endpoints were disease control rate (DCR) and 3-year survival rate. The therapeutic window for Chinese patients was 1.7-2.5 mg·h/L. The proportion of patients within the therapeutic window was 63.89% versus 28.33% (P < 0.0001), and the incidence of neutropenia was 68.33% versus 38.89% (P = 0.001) in the experimental group versus the control group in the sixth cycle, respectively. DCR was 72% versus 85% (P = 0.018) in the control group versus the experimental group. The 3-year survival rate of the PK group was significantly higher than that of the BSA group (P = 0.034). The PK-guided dosage adjustment of DTX could significantly increase the proportion of patients within the therapeutic window, decrease the incidence of neutropenia and increase the DCR and the 3-year survival rate. The PK-guided dosage adjustment based on the dynamic monitoring of AUC could be a useful method for oncologists to improve individualised treatment options, optimise drug efficacy and reduce drug toxicity.
Sections du résumé
BACKGROUND
Docetaxel (DTX) is a widely used anti-tumour drug, and its dosage is solely determined by body surface area (BSA). Adverse events, such as neutropenia or unsatisfied efficacy, likely occur because of differences in the pharmacokinetics (PK) and pharmacodynamics of patients. Thus, a feasible dosage adjustment method is needed.
METHODS
A total of 209 eligible patients who provided consent were enrolled and randomised into two groups to receive the BSA- and PK-guided dosage adjustments of DTX-based chemotherapy (3 weeks per cycle). The AUC of DTX was detected, and the therapeutic window for Chinese patients was determined. The proportion of patients within the therapeutic window was evaluated. Neutropenia was examined in accordance with the toxicity grading standard suggested by the World Health Organisation. Tumour response was assessed in accordance with Response Evaluation Criteria in Solid Tumors version 1.1. The primary endpoint was the incidence of neutropenia, and the secondary endpoints were disease control rate (DCR) and 3-year survival rate.
RESULTS
The therapeutic window for Chinese patients was 1.7-2.5 mg·h/L. The proportion of patients within the therapeutic window was 63.89% versus 28.33% (P < 0.0001), and the incidence of neutropenia was 68.33% versus 38.89% (P = 0.001) in the experimental group versus the control group in the sixth cycle, respectively. DCR was 72% versus 85% (P = 0.018) in the control group versus the experimental group. The 3-year survival rate of the PK group was significantly higher than that of the BSA group (P = 0.034).
CONCLUSIONS
The PK-guided dosage adjustment of DTX could significantly increase the proportion of patients within the therapeutic window, decrease the incidence of neutropenia and increase the DCR and the 3-year survival rate. The PK-guided dosage adjustment based on the dynamic monitoring of AUC could be a useful method for oncologists to improve individualised treatment options, optimise drug efficacy and reduce drug toxicity.
Identifiants
pubmed: 32513288
doi: 10.1186/s12967-020-02394-w
pii: 10.1186/s12967-020-02394-w
pmc: PMC7282138
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226Références
Int J Clin Oncol. 2013 Feb;18(1):96-104
pubmed: 22095245
J Clin Oncol. 2004 Jul 15;22(14):2901-8
pubmed: 15254059
J Clin Pharmacol. 2017 Feb;57(2):275-279
pubmed: 27479828
Pharmacogenetics. 1998 Oct;8(5):391-401
pubmed: 9825831
Lancet Oncol. 2016 Nov;17(11):e493-e501
pubmed: 27819247
Clin Cancer Res. 2011 Jan 15;17(2):353-62
pubmed: 21224369
Lancet Oncol. 2005 Apr;6(4):229-39
pubmed: 15811618
BMC Cancer. 2014 Mar 19;14:201
pubmed: 24641830
J Clin Oncol. 2012 Nov 1;30(31):3896-7
pubmed: 22965963
Pharmacogenomics J. 2016 Nov;16(6):519-524
pubmed: 26345519
Invest New Drugs. 2001 May;19(2):163-9
pubmed: 11392450
J Cancer Res Ther. 2011 Oct-Dec;7(4):412-5
pubmed: 22269401
Yakugaku Zasshi. 2009 Jun;129(6):749-57
pubmed: 19483418
Ann Oncol. 2007 Jan;18(1):168-72
pubmed: 17060489
Cancer Treat Rev. 2003 Oct;29(5):407-15
pubmed: 12972359
Clin Pharmacol Ther. 2005 Jan;77(1):43-53
pubmed: 15637530
Eur J Cancer. 2004 May;40(8):1170-8
pubmed: 15110880